Decision makes crucial cardiovascular imaging and CT-based technologies more economically viable to hospital outpatient and ambulatory care providers BOSTON – November 4, 2024 – Elucid Bioimaging, Inc. has announced a final rule from US Centers for Medicare &...
In the News
Elucid Receives U.S. 510(k) Clearance of PlaqueIQ™ Image Analysis Software to Aid Cardiovascular Disease Assessment
First and Only Software Validated on Ground-Truth Histology, the Gold Standard for Plaque Characterization BOSTON, Oct. 1, 2024 – Elucid has announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its PlaqueIQ™ imaging analysis...
Elucid Names Kelly Huang as CEO
Experienced commercial leader takes helm to expand cardiovascular diagnostic company globally and commercialize company’s flagship plaque analysis software BOSTON, July 22, 2024 – Elucid, a pioneering AI medical technology company providing physicians with imaging...
Elucid Commences International PRE-VUE CCT Registry Study
Multi-center, Retrospective Trial to Assess Prognostic Accuracy of Elucid’s Plaque and Plaque-based FFRCT Software in Patients with Clinically Indicated CCTA SCCT2024, WASHINGTON, D.C., and BOSTON, July 18, 2024 – Elucid, a pioneering AI medical technology company...
Elucid Moves into New Headquarters in Preparation for Commercial Launch
Modern Space Allows Room for Growth, Collaboration and Wellness BOSTON, June 27, 2024 -- Elucid, a pioneering medical technology company providing physicians with imaging analysis software based on ground truth histology to support treatment of cardiovascular disease,...
Expert Clinical Panel
Using CT Angiography to Categorize & Stratify Risk in Patients with Subclinical to Unstable Coronary Artery Disease
Gregg Stone, MD; Ron Blankstein, MD; Renu Virmani, MD; Joe Schoepf, MD; Tony Das, MD
Elucid Presents Data Demonstrating Its AI Software Can Uniquely Quantify Key Drivers of Heart Attack and Stroke from Computed Tomography
Elucid Founder, Andrew Buckler, To Present Findings at the SCCT Annual Scientific Meeting BOSTON--(BUSINESS WIRE)--Elucid, a medical technology company developing AI software for physicians to optimize the treatment of patients with known or suspected vascular...
Studies suggest Elucid’s AI software helps to objectively quantify key drivers of stroke and heart attack from computed tomography angiography (CTA)
Computed tomography angiography (CTA) has been increasingly used in the diagnosis of vascular disease and its a modality that offers many potential clinical benefits. The question is, how to actualize that benefit and get the most our of the modality. Elucid has developed an artificial intelligence software that might just answer that question.
Elucid Presents Results of the EVAPORATE Study at ESC Preventive Cardiology 2021 Late Breakers
Elucid Software Quantifies Plaque Morphology to Enable Better Assessment of IPE Treatment Effects BOSTON--(BUSINESS WIRE)--Elucid, a medical technology company developing AI software for physicians to optimize the treatment of patients with known or suspected vascular...
Study Demonstrates Elucid’s Ability to Estimate RNA Expression from Non-Invasive Cardiovascular Imaging
Early detection of high risk plaque phenotypes holds the promise to prevent myocardial infarction and ischemic stroke by enabling personalized therapeutics BOSTON--(BUSINESS WIRE)--Elucid, a medical technology company developing AI software to enable cardiovascular...